SMC accepts HRT treatment Bijuve for use across NHS Scotland
pharmafile | September 13, 2022 | News story | Manufacturing and Production |
The SMC has accepted HRT treatment, Bijuve, for use across NHS Scotland. Bijuve is the first and only body-identical HRT for estrogen deficiency symptoms in post-menopausal women, which combines estradiol and progesterone in a single daily oral capsule.
Women across Scotland will now be able to access this crucial product. HRT is used to relieve the symptoms of menopause, caused by hormone deficiency. The most common symptoms include hot fluhes, night sweats, vaginal dryness and discomfort during sex, difficulty sleeping, low mood or anxiety, reduced sex drive (libido), problems with memory and concentration.
There are different types of HRT, and treatments offer different combinations and dosages of hormones, as well as different administration methods, including tablets, patches, gels, and implants.
Dr Heather Currie, Gynaecologist and Associate Medical Director at Dumfries and Galloway Royal Infirmary, said, “This is really helpful for women in Scotland, and will offer another option for women who choose to take HRT. There is not one type or regimen which suits all women and having more options takes us a step closer to ensuring women across all nations in the UK are able to find a preparation that suits them.”
Dr Paula Briggs, Consultant in Sexual and Reproductive Health and Chair of the British Menopause Society, said, “The availability of a body-identical progesterone is welcome news for the women of Scotland. I am pleased to see more options for the treatment of menopause becoming available. As clinicians, it is vital we empower our patients to make well informed choices on what is available and what works best for them.”